LLY is trading at $884.99 (-3.6%) in pre-market action after Amazon announced the launch of a new GLP-1 obesity drug program, creating a significant new competitor in a key market for Eli Lilly. [12]
- Amazon's program integrates its One Medical telehealth and pharmacy services, streamlining patient access to GLP-1 therapies and directly challenging Eli Lilly's market position. [12]
- The move introduces a major distribution and patient engagement channel that could significantly influence prescription patterns and future revenue for Lilly's weight-loss drugs. [12]
- Broader market anxiety from escalating geopolitical tensions in the Strait of Hormuz and oil prices over $105 per barrel are also contributing to negative investor sentiment. [2, 9]